Cybin inc.: Cybin Inc. (the 'Company') doing business as Helus PharmaS (Nasdaq: HELP) (Cboe CA: HELP) ('Helus Pharma'), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced 'Heal-Us') and trade on Nasdaq with ticker symbol HELP.

According to BERNAMA News Agency, the interim chief executive officer of the Company, Eric So, stated, "Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004." Over the past several years, Helus Pharma has advanced its pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted.

Helus Pharma is approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the receipt of all necessary approvals. The new identity represents the company's current status and future aspirations as an innovative entity focused on redefining mental health care with the goal of helping minds heal.